AWM
NBIX icon

Axxcess Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Axxcess Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,664
Closed -$1.27M – 670
2022
Q4 		$1.27M Buy
+10,664
New +$1.25M 0.11% 185

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Axxcess Wealth Management's NBIX Position: Q1 2023 in Review

Axxcess Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 10,664 shares — an estimated $1.27M sold.

Axxcess Wealth Management first reported a position in NBIX in Q4 2022 and held it in 1 quarter. The position peaked at $1.27M in Q4 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • Axxcess Wealth Management reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
  • Axxcess Wealth Management sold 10,664 Neurocrine Biosciences shares in Q1 2023, an estimated $1.27M.
  • Axxcess Wealth Management first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 1 quarter.
  • Axxcess Wealth Management's Neurocrine Biosciences position peaked at $1.27M in Q4 2022.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Axxcess Wealth Management's 13F filing for Q1 2023, filed 3 May 2023.